List of Excipients in Branded Drug RESTORIL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
SpecGx LLC	RESTORIL	temazepam	0406-9915	ALCOHOL
SpecGx LLC	RESTORIL	temazepam	0406-9915	BUTYL ALCOHOL
SpecGx LLC	RESTORIL	temazepam	0406-9915	ETHYL ACETATE
SpecGx LLC	RESTORIL	temazepam	0406-9915	FD&C BLUE NO. 1
SpecGx LLC	RESTORIL	temazepam	0406-9915	FD&C RED NO. 3
SpecGx LLC	RESTORIL	temazepam	0406-9915	FERRIC OXIDE RED

RESTORIL Excipient Strategy and Commercial Opportunities for Temazepam Capsules

Last updated: August 20, 2026

Restoril is the branded formulation of temazepam, a Schedule IV benzodiazepine approved in the United States for short-term treatment of insomnia. Its active pharmaceutical ingredient, regulatory exclusivity, and original composition-of-matter protection are long expired. Commercial opportunity therefore lies in lower-cost supply, differentiated dosage forms, excipient substitution, formulation improvements, and controlled-substance manufacturing capability rather than in defending the legacy Restoril capsule.

What is Restoril and how is it positioned commercially?

Restoril contains temazepam, an orally administered benzodiazepine hypnotic. The reference product is marketed as capsules in 7.5 mg, 15 mg, 22.5 mg, and 30 mg strengths. The FDA label recommends short-term treatment, generally 7 to 10 days, and carries class warnings concerning abuse, misuse, dependence, withdrawal, respiratory depression, and use with opioids [1].

Attribute	Restoril
Active ingredient	Temazepam
Dosage form	Immediate-release hard gelatin capsule
Strengths	7.5 mg, 15 mg, 22.5 mg, 30 mg
Therapeutic class	Benzodiazepine hypnotic
FDA application	NDA 018163
Controlled-substance status	Schedule IV
Reference sponsor	Current labeling and marketing responsibility should be verified against the latest FDA and DailyMed records
Pediatric status	Not established for patients younger than 18 years
Primary commercial channel	Generic prescription market, with residual branded demand
Core formulation	Immediate-release capsule with conventional pharmaceutical excipients

Temazepam has a mature generic market. Generic manufacturers compete principally on acquisition cost, supply continuity, wholesaler contracts, pharmacy availability, and controlled-substance compliance. Brand Restoril has limited ability to command a premium without a differentiated delivery system or channel strategy.

What excipients are used in Restoril capsules?

Restoril uses conventional capsule excipients and shell components. FDA labeling identifies inactive ingredients for the marketed strengths, with colorants and capsule-shell composition varying by strength and manufacturer [1].

Typical excipient categories include:

Excipient category	Likely function	Commercial relevance
Lactose or another diluent	Bulking and dose uniformity	Low-cost, widely available; creates demand for lactose-free alternatives
Pregelatinized or pharmaceutical starch	Filler, binder, disintegration support	Mature supply market
Magnesium stearate	Lubricant	Low unit cost; potential impact on dissolution if overused
Microcrystalline cellulose	Diluent and compactability aid	More relevant to tablet or multiparticulate reformulations
Gelatin	Hard-capsule shell	Established supply chain; animal-origin restrictions create substitution opportunity
Titanium dioxide and colorants	Appearance and product identification	Regulatory and market pressure may favor color-minimized products
Purified water and shell-processing materials	Capsule manufacture	Relevant to capsule-shell suppliers and contract manufacturers

A manufacturer cannot assume that an excipient used in an approved Restoril or generic product is automatically suitable for every new temazepam dosage form. The proposed route, strength, daily exposure, patient population, and administration method determine the need for safety qualification and FDA review.

Which excipient issues are most important for temazepam?

The most important technical issues are content uniformity, capsule-filling performance, dissolution, powder flow, moisture control, and compatibility with the capsule shell. Temazepam products contain a small quantity of active ingredient relative to the total fill weight, so blend uniformity is a central development risk, particularly for the 7.5 mg strength.

Key development controls include:

• Particle-size distribution of temazepam and the principal diluent.
• Ordered mixing or geometric dilution for low-dose strengths.
• Lubricant concentration and blending time.
• Moisture uptake during storage.
• Shell brittleness and cross-linking risk.
• Dissolution across physiologically relevant pH conditions.
• Stability of colorants and capsule-shell components.
• Extractables and leachables for any new shell or packaging system.

The use of lactose can reduce cost but excludes patients with certain formulation preferences or perceived sensitivities. A lactose-free formulation based on microcrystalline cellulose, mannitol, dibasic calcium phosphate, or starch derivatives could support product differentiation, although the commercial value depends on measurable pharmacy and prescriber demand.

What commercial opportunities exist for Restoril excipients?

The strongest opportunities are in supply-chain replacement and differentiated formulations. Conventional excipients are commodities, but suppliers can create value through regulatory support, dual sourcing, low-moisture grades, controlled particle-size grades, and reliable supply for Schedule IV products.

1. Lactose-free and low-allergen capsules

A lactose-free temazepam capsule could target patients, prescribers, and health systems seeking simplified inactive-ingredient profiles. The product would need to preserve dissolution, content uniformity, stability, and capsule-filling performance.

Potential excipient platforms include:

• Microcrystalline cellulose and starch combinations.
• Mannitol-based fills.
• Dibasic calcium phosphate systems.
• Low-moisture, directly blendable diluents.
• Hypoallergenic capsule-shell systems.

The commercial proposition is stronger if the formulation removes several excipient concerns at once, rather than replacing lactose alone.

2. Gelatin-free capsule shells

Vegetarian capsule shells based on hypromellose or pullulan could address institutional, religious, vegetarian, and animal-origin preferences. The principal technical challenge is matching gelatin-shell performance for moisture permeability, mechanical strength, dissolution, and compatibility with the fill blend.

A gelatin-free Restoril alternative would likely require a new formulation and regulatory strategy. It would not be a simple manufacturing substitution if the change affects product performance or inactive-ingredient exposure.

3. Low-dose 7.5 mg formulation

The 7.5 mg strength creates a formulation opportunity because low-dose units are more sensitive to blend segregation and content-uniformity failures. A supplier could develop a pre-engineered excipient system that improves:

• Low-dose API distribution.
• Flow through automated capsule-filling equipment.
• Reduced segregation during transport.
• Faster dissolution without excessive disintegrant.
• Lower tablet or capsule weight.

This opportunity is operational rather than pharmacologically novel. A robust low-dose platform could support multiple benzodiazepine or other low-dose capsule products.

4. Sprinkle or administration-flexible products

A capsule that can be opened and sprinkled on soft food could address swallowing difficulty. The formulation must preserve dose uniformity, stability, and acceptability after opening. A sponsor would need to establish appropriate administration instructions and demonstrate that the capsule contents do not create unacceptable exposure changes.

A sprinkle product may be commercially relevant for older adults, long-term-care facilities, and patients with dysphagia. It also raises handling and diversion concerns because temazepam is controlled.

5. Orally disintegrating or rapidly dissolving formulations

An orally disintegrating tablet, mini-tablet, or rapidly dispersible multiparticulate product could provide a differentiated delivery system. Potential excipient technologies include:

• Mannitol-based rapidly disintegrating matrices.
• Crospovidone or croscarmellose sodium.
• Taste-masking polymers.
• Drug-loaded multiparticulates.
• Low-moisture compression systems.

Taste masking is a material issue because temazepam is administered orally and may be exposed in the mouth in an ODT. The product would also need to avoid creating a rapid-onset profile that increases misuse or respiratory-depression risk.

What FDA pathway applies to a new Restoril formulation?

A conventional generic capsule generally uses the abbreviated new drug application pathway under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. A materially differentiated formulation may require a 505(b)(2) application [2].

Product concept	Likely FDA pathway	Main evidence burden
Same-strength immediate-release capsule with permissible excipient differences	ANDA	Bioequivalence, pharmaceutical equivalence, quality and stability
Lactose-free capsule with same release profile	ANDA or 505(b)(2), depending on formulation and reference-product comparison	Bioequivalence, excipient justification, quality data
Gelatin-free capsule shell	ANDA if pharmaceutical equivalence and bioequivalence are established; otherwise 505(b)(2)	Shell performance, dissolution, stability, bioequivalence
Sprinkle capsule	Often 505(b)(2) or a complex ANDA strategy	Administration study, content uniformity after opening, stability
ODT or oral film	Usually 505(b)(2)	Pharmacokinetics, local tolerability, taste, safety, abuse-risk assessment
Modified-release product	505(b)(2) or full NDA depending on reliance and novelty	Comparative pharmacokinetics, clinical justification, abuse and safety analysis
Pediatric formulation	505(b)(2) or NDA supplement depending on sponsor rights	Pediatric safety, dosing, acceptability, and regulatory plan

FDA’s Inactive Ingredient Database can support excipient selection, but database presence is not a guarantee that a new formulation will receive approval. The sponsor must evaluate maximum daily exposure, route, dosage form, population, and formulation-specific safety [3].

What patents protect Restoril and temazepam?

The original temazepam patent estate and the regulatory exclusivity associated with Restoril are exhausted. Temazepam entered the market decades ago, and the active pharmaceutical ingredient is available through generic manufacturers.

Protection category	Current strategic status
Temazepam composition-of-matter patents	Expired
Original Restoril formulation patents	Expired or commercially immaterial
New-product exclusivity for the legacy capsule	Expired
Orphan exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Patent protection for a new excipient system	Potentially available if the formulation is novel and non-obvious
Method-of-use protection	Limited practical value for the established insomnia indication
Device or packaging protection	Potentially available for a new administration or diversion-control system

A new formulation patent could cover a specific excipient ratio, particle-size distribution, capsule shell, multiparticulate structure, manufacturing process, or dissolution profile. Broad claims directed only to administering temazepam for insomnia would face substantial validity and obviousness pressure because the active ingredient and indication are longstanding.

A stronger patent program would combine:

1. Composition claims directed to a defined excipient system.
2. Process claims covering blend preparation, encapsulation, or moisture control.
3. Performance claims tied to dissolution or stability.
4. Dosage-form claims covering sprinkle, ODT, multiparticulate, or abuse-deterrent delivery.
5. Packaging or administration-device claims where relevant.

What is the Orange Book status of Restoril?

Restoril is an old small-molecule drug with no meaningful period of unexpired regulatory exclusivity. The current Orange Book entry for NDA 018163 and any listed patents should be checked before an ANDA filing or Paragraph IV certification [4].

For commercial planning, the practical assumptions are:

• Generic temazepam products are available.
• The legacy capsule has no durable exclusivity barrier.
• An ANDA sponsor must address the reference listed drug’s labeling and bioequivalence requirements.
• A new formulation may require 505(b)(2) reliance rather than a conventional ANDA.
• Any current patent listing must be assessed for scope, expiration, pediatric extensions, and enforceability.

Which companies are challenging Restoril exclusivity?

Restoril is not a current high-value exclusivity target. Generic temazepam products have been marketed for years, and commercial competition is dispersed across multiple generic manufacturers. Publicly significant Paragraph IV litigation is not a central feature of the Restoril market.

The principal competitive risk is therefore ordinary generic price erosion, supply disruption, and channel substitution rather than a single high-profile patent challenge. A new branded formulation would face competition from established generic capsules and from alternative insomnia products, including zolpidem, eszopiclone, zaleplon, low-dose doxepin, suvorexant, lemborexant, daridorexant, and nonprescription sleep products.

How strong is the patent estate for a new temazepam formulation?

A new temazepam formulation can have a moderate patent position if it solves a defined technical or commercial problem. The estate is weak if it relies only on routine excipient substitution.

Patent strategy	Expected strength
Replacing lactose with another standard diluent	Low unless linked to unexpected performance
Gelatin-free shell with demonstrated stability or dissolution advantage	Moderate
Low-dose blend with improved content uniformity	Moderate if supported by comparative data
Sprinkle formulation with defined administration performance	Moderate to strong
ODT with rapid disintegration and controlled exposure	Moderate, subject to prior-art review
Modified-release temazepam	Potentially strong, but clinical and safety burden is high
Abuse-deterrent formulation	Potentially strong, with substantial development cost
Packaging-only patent	Narrow but commercially useful if tied to controlled-substance handling

Patentability depends on the full prior-art record, including legacy temazepam formulations, benzodiazepine delivery systems, capsule-shell technologies, and controlled-release hypnotic products. Commercial enforceability also depends on whether generic substitution can avoid the claimed excipient or process limitations.

What manufacturing and intellectual-property barriers exist?

The main manufacturing barriers are not chemical synthesis. They are controlled-substance handling, blend uniformity, analytical sensitivity, validation, and supply-chain controls.

A sponsor must manage:

• DEA registration and Schedule IV inventory controls.
• Secure storage and transportation.
• Diversion monitoring.
• Batch reconciliation and reconciliation of rejects.
• Low-dose content-uniformity validation.
• Capsule-shell supply and colorant changes.
• Supplier qualification for pharmaceutical-grade excipients.
• Stability under temperature and humidity stress.
• Cleaning validation for potent, low-dose benzodiazepine products.

A formulation company can create defensible value by qualifying multiple suppliers, establishing a proprietary premix, controlling excipient particle size, or designing a capsule shell that supports predictable dissolution. These measures can support trade-secret protection even where patent claims are narrow.

How does Restoril compare with competing insomnia drugs?

Restoril’s main commercial disadvantage is its mature generic status and benzodiazepine safety profile. Newer insomnia drugs may command higher prices because they have branded patents, differentiated mechanisms, or longer exclusivity periods.

Product class	Patent and exclusivity position	Excipient opportunity	Main commercial issue
Temazepam capsules	Mature, generic	Low-cost, lactose-free, gelatin-free, sprinkle, ODT	Price competition and controlled-substance risk
Zolpidem immediate-release	Mature generic	ODT, sublingual, modified release	Broad generic competition
Eszopiclone	Mature generic	Taste masking, alternate dosage forms	Generic price erosion
Orexin antagonists	Active branded and patent-driven markets	Modified release, tablet performance, packaging	Higher development cost and clinical differentiation
Low-dose doxepin	Generic	Low-dose uniformity and liquid or mini-tablet systems	Low-dose formulation complexity
Melatonin products	Predominantly nonprescription	Extended release, taste, stability	Quality and channel fragmentation

Restoril has a lower development barrier than a new molecular entity but a smaller pricing opportunity. The most credible commercial strategy is a targeted formulation with clear pharmacy, institutional, or patient-use value.

What generic launch scenarios exist for a new Restoril product?

A new entrant has four realistic launch models:

1. A low-cost ANDA capsule competing on supply reliability and contract pricing.
2. A differentiated 505(b)(2) product targeting lactose-free, gelatin-free, sprinkle, or ODT administration.
3. A specialty-channel product for long-term-care, geriatric, or dysphagia populations.
4. A licensing model based on an excipient platform that can be applied to several low-dose controlled substances.

The first model has the lowest regulatory risk and the lowest margin potential. The second and third models offer higher pricing but require stronger clinical, regulatory, and commercial support. The fourth model can increase platform value if the excipient technology applies beyond temazepam.

Key Takeaways

• Restoril is temazepam, an established Schedule IV benzodiazepine marketed as immediate-release capsules.
• Original patent and regulatory exclusivity barriers have expired.
• Conventional excipients are largely commoditized.
• The strongest formulation opportunities are lactose-free capsules, gelatin-free shells, low-dose blend systems, sprinkle products, and ODTs.
• A conventional generic is generally an ANDA opportunity; materially differentiated products may require 505(b)(2).
• New patent value must come from a specific excipient system, manufacturing process, dosage form, or performance attribute.
• Biosimilar risk does not apply because temazepam is a small molecule.
• The main competitive threats are generic price erosion, established pharmacy substitution, and alternative insomnia therapies.
• Controlled-substance compliance and low-dose content uniformity are major manufacturing barriers.
• A differentiated formulation can support licensing or specialty-channel commercialization, but a standard capsule is unlikely to generate substantial brand economics.

FAQs About Restoril Excipient and Formulation Strategy

Can temazepam capsules be made without lactose?

Yes. Lactose can be replaced with microcrystalline cellulose, mannitol, starch-based excipients, or other suitable diluents, subject to formulation, stability, dissolution, and regulatory requirements.

Is a gelatin-free Restoril capsule commercially viable?

It can be viable for selected patient and institutional segments. Hypromellose and pullulan shells are the most relevant alternatives, but shell performance and bioequivalence must be demonstrated.

Does Restoril have biosimilar competition?

No. Temazepam is a synthetic small molecule, so competition occurs through generic drug applications rather than biosimilar applications.

Can a new temazepam formulation receive market exclusivity?

Potentially. A novel formulation may qualify for patent protection and, depending on the FDA pathway and product attributes, regulatory exclusivity. The protection would attach to the new product, not to legacy temazepam itself.

Which Restoril formulation has the highest commercial potential?

A differentiated product that combines low-dose uniformity, lactose-free excipients, a gelatin-free shell, and administration flexibility has a stronger commercial proposition than a conventional capsule. The exact opportunity depends on reimbursement, pharmacy substitution, institutional purchasing, and the evidence supporting improved use.

References

1. U.S. Food and Drug Administration. (n.d.). Restoril (temazepam) capsules prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2).
3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.